Search results for "Lymph"

showing 10 items of 4590 documents

Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI

2021

Yes

medicine.medical_specialtyPatientsCKD-EPI:Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders [Medical Subject Headings]Dosislcsh:RC870-923:Anatomy::Cardiovascular System::Blood Vessels::Arteries::Aorta [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]DosageRivaroxabanRivaroxabánmedicineRenal insufficiency chronicInsuficiencia renal crónicaGynecology:Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency Chronic [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Observational Study as Topic [Medical Subject Headings]business.industry:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Dosage Calculations [Medical Subject Headings]lcsh:Diseases of the genitourinary system. Urology:Persons::Persons::Patients [Medical Subject Headings]NephrologyPacientesDosificaciónbusiness:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Prescriptions [Medical Subject Headings]Nefrología
researchProduct

Risk factors for refractory Kawasaki disease: clinical records of the paediatric clinic of palermo

2014

Kawasaki disease (KD) is an acute, self-limited febrile illness that mainly affecting small- to medium-sized vessels and occurs in early childhood. The etiology is currently unknown, however it likely results from an immunologic response triggered by microbial agents, with documented genetic susceptibility. Intravenous administration of immunoglobulin (IVIG) is the gold standard therapy for coronary arteritis in the acute phase of KD; some patients do not respond to IVIG and coronary aneurysms continue to develop in 5%. The most serious complications are coronary vasculitis and aneurysms. 15% of these patients do not respond to IVIG (Refractory KD:RMK) and have a higher risk of aneurysms.

medicine.medical_specialtyPediatricsbiologybusiness.industryGold standardmedicine.diseaseRheumatologySettore MED/38 - Pediatria Generale E SpecialisticaRefractoryRheumatologyhemic and lymphatic diseasesInternal medicinePoster PresentationPediatrics Perinatology and Child HealthmedicineGenetic predispositionEtiologybiology.proteinImmunology and AllergyKawasaki diseaseKawasaki disease risk factorsPediatrics Perinatology and Child HealthAntibodyVasculitisbusinessPediatric Rheumatology
researchProduct

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

2016

Abstract Background: Management of anemia is a common therapeutic challenge in patients with myelodysplastic syndromes (MDS). Luspatercept (ACE-536), a fusion protein containing modified activin receptor type IIB, is being developed for treatment of anemia in lower-risk MDS. Luspatercept binds GDF11 and other TGF-β superfamily ligands to promote late-stage erythroid differentiation and increase hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014 and Attie K, Am J Hematol, 2014). Aims: This is an ongoing, phase 2, multicenter, open-label study to evaluate the effects of luspatercept in patient (pts) with low-intermediate risk MDS. Endpoints included erythroid response (IWG HI-E), RBC transfus…

medicine.medical_specialtyPediatricsbusiness.industryAnemiaMyelodysplastic syndromesImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyhemic and lymphatic diseasesPharmacodynamicsInternal medicineLuspaterceptCohortmedicineIntermediate riskbusinessLenalidomidemedicine.drugBlood
researchProduct

Die kombinierte operative und radiotherapeutische Behandlung (CORT) von Beckenwandrezidiven: Erfahrungsbericht nach 3 Jahren

1993

CORT has been developed to treat recurrent gynaecological malignancies infiltrating the pelvic wall unilaterally. The surgical part consists of: (i) staging laparotomy/lymphadenectomy, (ii) maximum tumour resection at the pelvic wall and exenteration of infiltrated central pelvic organs, (iii) implantation of guiding tubes on the residual tumour/tumour bed on the pelvic wall, (iv) pelvic wall plasty with muscle, musculocutaneous and omentum flaps, (v) operative reconstruction of bowel, bladder and perineo-vulvo-vaginal functions. Radiation is performed as interstitial high dose rate brachytherapy through the implanted tubes. Patients without prior pelvic irradiation receive in addition, who…

medicine.medical_specialtyPelvic exenterationEpitheliomabusiness.industrymedicine.medical_treatmentObstetrics and GynecologyWhole-Pelvismedicine.diseaseHigh-Dose Rate BrachytherapySurgeryRadiation therapyMaternity and MidwiferymedicineCarcinomaLymphadenectomybusinessComplicationGeburtshilfe und Frauenheilkunde
researchProduct

Distribution of lymphocyte surface antigens in healthy neonates.

1994

Using flow cytometric analysis we investigated the distribution of major lymphocyte surface antigens in newborn infants. A total of 221 newborns entered the study, of whom 53 fullfilled our criteria of healthy mature neonates. Percentages of immunofluorescent-positive cells were as follows (median and range from 25th to 75th percentiles given): for CD1 3.8%; 2.3%–5.8%. CD2 60.9%; 52.4%–66.8%. CD3 57.5%; 50.5%–63.3%. TcRas 57.7%; 48.1%–60.0%. CD4 36.3%; 28.0%–42.6%. CD8 23.0%; 20.0%–27.4%. CD11a 56.3%; 46.3%–68.5%. CD19 12.1%; 8.6%–14.8%. CD20 10.9%; 8.4%–12.9%. CD25 2.6%; 2.1%–4.5%. CDw52 61.0%; 51.2%–76.1%. CD71 5.2%; 3.1%–9.3%. While the ranges for the percentage of immunofluorescent-posi…

medicine.medical_specialtyPercentilebusiness.industryLymphocyteInfant NewbornNormal valuesFetal BloodFlow CytometryGastroenterologyAntigens DifferentiationSurgerymedicine.anatomical_structureAntigenAntigens CDReference ValuesRecien nacidoInternal medicinePediatrics Perinatology and Child HealthmedicineHumansbusinessEuropean journal of pediatrics
researchProduct

Incidence, Risk Factors and Management of Symptomatic Lymphoceles after Radical Retropubic Prostatectomy

2017

Abstract Introduction We investigated the incidence, clinical course and risk factors for symptomatic lymphoceles after radical retropubic prostatectomy with pelvic lymph node dissection. Moreover, we explored parameters for the failure of percutaneous lymphocele drainage. Methods The incidence of symptomatic lymphoceles in patients with prostate cancer who underwent radical retropubic prostatectomy with pelvic lymph node dissection in our department between 2008 and 2013 was investigated retrospectively. The occurrence of lymphoceles was correlated with several clinical and histopathological parameters. In addition, logistic regression analysis was performed to assess the value of independ…

medicine.medical_specialtyPercutaneousbusiness.industryProstatectomyUrologymedicine.medical_treatment030232 urology & nephrologymedicine.diseaseSurgery03 medical and health sciencesDissectionLymphocele0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesismedicineLymphRisk factorbusinessLymph nodeRadical retropubic prostatectomyUrology Practice
researchProduct

Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

2011

Abstract Abstract 2708 Background: The simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) has been shown to be a good predictor of patient survival (Blood 2008;111:558–65; Blood 2010;115:1530–1533). This post hoc study analyzed data from a randomized, phase III clinical trial investigating temsirolimus (TEM) in relapsed/refractory mantle cell lymphoma (MCL) in which TEM 175/75 (175 mg for first 3 weeks then 75 mg weekly) demonstrated significantly longer progression-free survival (PFS) vs investigator's choice of therapy (INV; 4.8 vs 1.9 months, respectively; hazard ratio [HR]=0.44; P=.0009; J Clin Oncol 2009;27:3822–9). Patients receiving TEM 175/25 (175 mg for first 3 w…

medicine.medical_specialtyPerformance statusAnemiabusiness.industryIncidence (epidemiology)ImmunologyHazard ratioCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyTemsirolimusInternational Prognostic IndexRenal cell carcinomaInternal medicinemedicineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma

2021

(1) Background: Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy. Besides tumor, nodal, and metastatic status, the UICC TNM classification describes further parameters such as lymphangio- (L0/L1), vascular (V0/V1/V2), and perineural invasion (Pn0/Pn1). The aim of this study was to analyze the influence of these parameters on recurrence and survival. (2) Methods: All surgical explorations for patients with ICC between January 2008 and June 2018 were collected and further analyzed in our institutional database. Statistical analyses focused on perineural, lymphangio-, and vascular invasion examined histologically and their influence on tumor recurrence and survival. (3) Results: Of 2…

medicine.medical_specialtyPerineural invasionMalignancyGastroenterologysurvivalArticleResectionVascular invasion03 medical and health sciences0302 clinical medicineintrahepatic cholangiocarcinomaInternal medicineStatistical analysesmedicineOverall survivalvascular invasionliver surgeryIntrahepatic Cholangiocarcinomabusiness.industryRlymphangioinvasionGeneral Medicineperineural invasionmedicine.diseaseTumor recurrence030220 oncology & carcinogenesisMedicine030211 gastroenterology & hepatologybusinessJournal of Clinical Medicine
researchProduct

Clinical conditions responsible for hyperviscosity and skin ulcers complications

2017

In this brief review, we have examined some clinical conditions that result to be associated to an altered hemorheological profile and at times accompanied by skin ulcers. This skin condition may be observed in patients with the following condtions, such as primary polycythemic hyperviscosity (polycythemia, thrombocytemia) treated with hydroxyurea, primary plasma hyperviscosity (multiple myeloma, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia, and connective tissue diseases), primary sclerocythemic hyperviscosity (hereditary spherocytosis, thalassemia, and sickle cell disease). In addition, it may be present in patients with secondary hyperviscosity conditions such as diabetes mell…

medicine.medical_specialtyPhysiologyChronic venous insufficiencyBlood viscosityHyperviscosity syndromeCryofibrinogenemiaHyperviscosity030204 cardiovascular system & hematologyGastroenterologyHyperviscosity syndrome; blood viscosity; skin ulcers030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineskin ulcershemic and lymphatic diseasesPhysiology (medical)Internal medicineHyperviscosity syndromeSkin UlcermedicineHumansbusiness.industryHematologyCritical limb ischemiaSkin ulcermedicine.diseaseCryoglobulinemiablood viscositymedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Adipose Tissue: ILC2 Crank Up the Heat

2015

White-to-beige conversion of adipocytes is one of the most promising approaches to therapeutically target obesity; however, the signals driving this process had largely remained unclear. Recently, two publications, Brestoff et al. (2014) in Nature and Lee et al. (2015) in Cell, showed that group 2 innate lymphoid cells directly regulate adipocyte differentiation and drive the growth of beige fat.

medicine.medical_specialtyPhysiologyInnate lymphoid cellInnate immunologyAdipose tissueCell BiologyBiologychemistry.chemical_compoundEndocrinologychemistryAdipocyteInternal medicinemedicineMolecular BiologyCell Metabolism
researchProduct